

# **Dosimetry *in vitro* – an under appreciated problem?**

ABHINAV KUMAR

# Nanomedicine Market to Cross \$160 Billion by 2015


Global Market for Nanomedicine –  
Global Industry Analysts Inc.

## Challenges

1. Toxicity issues with nanomaterials

2. Issues with scaling up production

3. Lack of regulatory framework



Rationale

Particle Characterization

Particokinetics


Conventional Cytotoxicity VS Particokinetics & Cytotoxicity

# Limitations of Existing Systems

- Insufficient particle characterization prior to toxicity testing
- Deficiencies in assay design (selection of cell types, time of exposure and dose range)
- Lack of consideration of particle kinetics (dosimetry)



# Particle Characterization In Relevant Assay Medium



Particles aggregate in CCM without FBS and aggregation is a gradual process

Rationale


Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Zeta Potential is Affected by Suspension Media

Zeta Potential of NP Under Different *In Vitro* Media @ 37°C




**Particles have roughly same ZP in CCM + 2%FBS**



# Nanoparticles Oxidative Potential Using Ascorbic Acid Depletion Assay


Absorbance measured at 265 nm



t=0

Ascorbic acid  
absorption


A1



t=2

Ascorbic acid  
absorption

A2



t=4

Ascorbic acid  
absorption

A3

**A1>A2>A3..... Absorbance of ascorbic acid measured every 2 min for 120 min**


Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Manufacturing Process Does Not Contaminate SLN's Surface




Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Dosimetry: Do All Particles Reach Cells?



Clift *et. al.*  
2008

Rationale


Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity



# Dosimetry: Do All Particles Reach Cells?



Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# How Do We Model Cellular Dose?

**Gravitational** sedimentation can be determined using Stoke's Law:

$$\text{Settling Velocity} = \frac{2r^2 g (\rho_p - \rho_m)}{9\eta}$$

Where

- $g$  is the gravitational acceleration)
- $\rho_p$  is the density of the particle
- $\rho_m$  is the density of the medium
- $\eta$  is the viscosity of medium
- $r$ , the radius of the particle

**Diffusional** contribution can be determined using Fick's Law:

$$\frac{\partial c}{\partial t} = \frac{D \partial^2 c}{\partial z^2}$$

Where:

- $c$  is the particle's concentration
- $D$  is the diffusion coefficient
- $t$  is the time
- $z$  is the spatial coordinate (from bottom to top of the culture well)


Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# How Do We Measure Cellular Dose?



## METHOD

Fluorescent PS50 and PS200nm particles were added to cells

After 4 h incubation with particles cells were lysed

Fluorescence of cell lysate was measured at 469 nm Excitation and 508 nm Emission


Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Cellular Dose < 20% of Nominal Dose




Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Cellular Dose < 20% of Nominal Dose



Predicted dose correlates well with observed dose


Rationale

Particle Characterization


Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Nominal Dose Underestimates Cytotoxicity of CuO



▽ Nominal SA Dose ( $\text{cm}^2/\text{cm}^2$ )



○ Cellular SA Dose ( $\text{cm}^2/\text{cm}^2$ )


Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Nominal Dose Underestimates Cytotoxicity of LNC 50



▽ Nominal SA Dose (cm<sup>2</sup>/cm<sup>2</sup>)

○ Cellular SA Dose (cm<sup>2</sup>/cm<sup>2</sup>)

Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# Nominal Dose Underestimates Cytotoxicity

Cell Type	Particle Type	NOMINAL SA DOSE	CELLULAR SA DOSE
		IC <sub>50</sub> (cm <sup>2</sup> /cm <sup>2</sup> )	IC <sub>50</sub> (cm <sup>2</sup> /cm <sup>2</sup> )
A549	CuO 6 h	1	0.5
	CuO 24 h	0.8	0.8
	LNC 50	55	3

Rationale


Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity



# Toxicity Associated Is Due To Solutol



Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# *In Vitro-In Vivo* Correlation

## Assessing Toxicity of Fine and Nanoparticles: Comparing *In Vitro* Measurements to *In Vivo* Pulmonary Toxicity Profiles

Christie M. Sayes, Kenneth L. Reed, and David B. Warheit<sup>1</sup>

*DuPont Haskell Laboratory for Health and Environmental Sciences, Newark, Delaware 19714*

When considering the range of toxicity end points to five different particle types, the comparisons of *in vivo* and *in vitro* measurements **demonstrated little correlation**, particularly when considering many of the variables assessed in this study—such as cell types to be utilized, culture conditions and time course of exposure, as well as measured end points. It seems clear that ***in vitro* cellular systems will need to be further developed**, standardized, and validated (relative to *in vivo* effects) in order to provide useful screening data on the relative toxicity of inhaled particle types.

Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

# What Are The Implications?

## Particle Characterization

- Size Is Affected By Suspension Media
- Aggregation Is A Gradual Process

## Dosimetry

- Way of Expressing Dose Can Skew The Interpretation of Results
- Cellular SA Dose Should Be Used To Express *In Vitro* Results

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity

Conclusion

# Acknowledgements


- I would like to thank my supervisors Dr. Ben Forbes, Dr. Lea Ann Dailey and Dr. Ian Mudway
- Many thanks to ESPRC and Unilever Ltd for their generous funding for this project
- Thanks to all the project students



**Thank You**



# Threshold Dose *In Vivo* Results



The dose-response *in vivo* using normalised dose ( $\text{cm}^2/\text{cm}^2$ ).

Rationale

Particle Characterization

Particokinetics

Conventional Cytotoxicity VS  
Particokinetics & Cytotoxicity